These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Goel A; Carlson SK; Classic KL; Greiner S; Naik S; Power AT; Bell JC; Russell SJ Blood; 2007 Oct; 110(7):2342-50. PubMed ID: 17515401 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein. Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969 [TBL] [Abstract][Full Text] [Related]
5. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus. Zhang P; Han X; Tan W; Chen D; Sun Q Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430 [TBL] [Abstract][Full Text] [Related]
6. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants. Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872 [TBL] [Abstract][Full Text] [Related]
8. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis Virus. Gao Y DNA Cell Biol; 2024 Feb; 43(2):57-60. PubMed ID: 38079267 [TBL] [Abstract][Full Text] [Related]
10. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628 [TBL] [Abstract][Full Text] [Related]
11. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245 [TBL] [Abstract][Full Text] [Related]
12. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699 [TBL] [Abstract][Full Text] [Related]
13. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Naik S; Nace R; Barber GN; Russell SJ Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623 [TBL] [Abstract][Full Text] [Related]
14. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum. Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134 [TBL] [Abstract][Full Text] [Related]